Clinical Trial News and Research

RSS

Valtech receives CE Mark approval for Cardioband Mitral Reconstruction System

Valtech Cardio, Ltd.,, an innovator in the development of devices for mitral and tricuspid valve repair and replacement, announced today it has received Conformite Europeenne (CE) Marking for its Cardioband Mitral Reconstruction System (Cardioband), a proprietary, implantable mitral reconstruction device with a transfemoral, transseptal delivery system for mitral valve repair.

14 Sep 2015

Caltech researchers find antibody that can detect, neutralize HIV viruses in infected patients

Proteins called broadly neutralizing antibodies (bNAbs) are a promising key to the prevention of infection by HIV, the virus that causes AIDS. bNAbs have been found in blood samples from some HIV patients whose immune systems can naturally control the infection.

14 Sep 2015

Mirati to present data on tyrosine kinase inhibitor at ESMO 2015 European Cancer Congress

Mirati Therapeutics, Inc., an oncology company focusing on genetic and epigenetic drivers of cancer, today announced it will present data on its tyrosine kinase inhibitor, MGCD516, at the ESMO 2015 European Cancer Congress being held in Vienna, Austria from September 25-29, 2015.

11 Sep 2015

Aridis' AR-301 granted FDA Fast Track Designation for treatment of pneumonia caused by S. aureus

Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, announced today that the U.S. Food and Drug Administration granted Fast Track Designation to AR-301, the Company's fully human anti-Staphylococcal alpha-toxin IgG1 monoclonal antibody (mAb).

11 Sep 2015

New collaboration may allow researchers to develop potential gene therapies for pediatric diseases

A new collaboration between Seattle Children's Research Institute and bluebird bio, Inc., a biotechnology company based in Cambridge, Mass. and Seattle, will allow researchers to develop potentially transformative gene therapies for severe genetic and rare pediatric diseases. The collaboration supports pediatric researchers in Seattle who will work with bluebird bio scientists and the company's gene editing technology to research potential cures for genetic pediatric diseases.

11 Sep 2015

Targeting exhausted immune cells may change prognosis for leukemia relapse patients after transplant

Targeting exhausted immune cells may change the prognosis for patients with acute myeloid leukemia (AML) relapse after a stem cell transplant, according to Penn State College of Medicine researchers.

11 Sep 2015

Researchers find key cellular enzyme that could be effective drug target for urologic cancer cells

Researchers at the SUNY Upstate Medical University have found that a key cellular enzyme, c-Abl, could be an effective drug target in cancer cells for urologic cancers, such as prostate and kidney.

11 Sep 2015

Modified Story Memory Technique improves memory in adults with moderate to severe TBI

Kessler Foundation researchers published results of a randomized clinical trial (RCT) of a cognitive intervention to improve learning and memory in individuals with traumatic brain injury (TBI) - the TBI-MEM trial.

11 Sep 2015

Research: Cancer preventative surgery may not be necessary in the future

Surgery to remove the breasts of women at increased risk of developing breast cancer may not be necessary in the future, according to research published in EBioMedicine. Two new studies looking at the effect the menstrual cycle has on the development of breast and ovarian cancer reveal alternative prevention strategies that may render surgery unnecessary.

11 Sep 2015

Scientists elucidate genetic interaction that may prove key to development, progression of glaucoma

Scientists at the University of California, San Diego School of Medicine have elucidated a genetic interaction that may prove key to the development and progression of glaucoma, a blinding neurodegenerative disease that affects tens of millions of people worldwide and is a leading cause of irreversible blindness.

11 Sep 2015

Masayo Takahashi awarded inaugural Ogawa-Yamanaka Stem Cell Prize

The Gladstone Institutes is pleased to present the inaugural Ogawa-Yamanaka Stem Cell Prize to Masayo Takahashi, MD, PhD, a faculty member and project leader in the Laboratory for Retinal Regeneration at the RIKEN Centre for Developmental Biology in Japan.

10 Sep 2015

First patient dosed in long term-safety extension study of Resolaris for adult patients with FSHD

aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe rare diseases, today announced that the first patient has been dosed in a newly initiated long term-safety extension study of Resolaris for adult patients with facioscapulohumeral muscular dystrophy (FSHD), a rare and severe genetic myopathy for which there are currently no approved treatments.

10 Sep 2015

DelMar presents updated VAL-083 Phase I/II trial data at GBM2015 meeting

DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today presented updated clinical data from its Phase I/II study of lead product candidate VAL-083 (dianhydrogalactitol), in patients with refractory glioblastoma multiforme (GBM), at GBM2015: 2nd International Symposium on Clinical and Basic Investigation in Glioblastoma in Toledo, Spain.

10 Sep 2015

CureVac, IAVI team up to advance development, testing of AIDS vaccines

The non-profit International AIDS Vaccine Initiative (IAVI) and biopharmaceutical company CureVac are partnering to accelerate the development of AIDS vaccines, utilizing novel immunogens developed by IAVI and partners, delivered via CureVac's novel messenger RNA (mRNA) technology.

10 Sep 2015

A new approach to prevent breast and ovarian cancer

Surgery to remove the breasts of women at increased risk of developing breast cancer may not be necessary in the future, according to research published in EBioMedicine.

10 Sep 2015

Innovative vaccine therapy shows promise against glioblastoma brain tumors

An innovative vaccine therapy developed at Roswell Park Cancer Institute is being tested in a multisite clinical trial involving 50 patients with newly diagnosed glioblastoma brain tumors. The phase II study, now accruing patients at both Roswell Park and the Cleveland Clinic, will assess the effectiveness of the SurVaxM vaccine in combination with standard chemotherapy as treatment for this often-fatal cancer.

10 Sep 2015

New study examines effect of exercise on outcomes for older breast cancer survivors

Physician-scientists at University Hospitals Case Medical Center's Seidman Cancer Center and Case Western Reserve University School of Medicine are leading a new study exploring the impact of exercise on outcomes for older breast cancer survivors.

9 Sep 2015

MD Anderson's Jim Allison named winner of 2015 Lasker-DeBakey Clinical Medical Research Award

For inventing a completely new way to strike cancer by unlocking a shackled immune system attack, Jim Allison, Ph.D., chair of Immunology at The University of Texas MD Anderson Cancer Center, will receive the nation's highest honor for clinical medical research.

9 Sep 2015

Oxis Biotech executes worldwide license agreement to develop, commercialize novel cancer therapy

Oxis Biotech, Inc., a wholly owned subsidiary of Oxis International, Inc., announced today the execution of an exclusive worldwide license agreement to further develop and commercialize DT2219ARL, a novel therapy for the treatment of various human B cell cancers, leukemias and lymphomas.

8 Sep 2015

FDA grants Orphan Drug designation to Rigel's Fostamatinib for treatment of patients with ITP

Rigel Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has granted Orphan Drug designation to Fostamatinib, Rigel's oral spleen tyrosine kinase (SYK) inhibitor which is currently in Phase 3 clinical studies in patients with chronic immune thrombocytopenic purpura (ITP).

8 Sep 2015

Clinical Trial News and Research

Valtech receives CE Mark approval for Cardioband Mitral Reconstruction System

Caltech researchers find antibody that can detect, neutralize HIV viruses in infected patients

Mirati to present data on tyrosine kinase inhibitor at ESMO 2015 European Cancer Congress

Aridis' AR-301 granted FDA Fast Track Designation for treatment of pneumonia caused by S. aureus

New collaboration may allow researchers to develop potential gene therapies for pediatric diseases

Targeting exhausted immune cells may change prognosis for leukemia relapse patients after transplant

Researchers find key cellular enzyme that could be effective drug target for urologic cancer cells

Modified Story Memory Technique improves memory in adults with moderate to severe TBI

Research: Cancer preventative surgery may not be necessary in the future

Scientists elucidate genetic interaction that may prove key to development, progression of glaucoma

Masayo Takahashi awarded inaugural Ogawa-Yamanaka Stem Cell Prize

First patient dosed in long term-safety extension study of Resolaris for adult patients with FSHD

DelMar presents updated VAL-083 Phase I/II trial data at GBM2015 meeting

CureVac, IAVI team up to advance development, testing of AIDS vaccines

A new approach to prevent breast and ovarian cancer

Innovative vaccine therapy shows promise against glioblastoma brain tumors

New study examines effect of exercise on outcomes for older breast cancer survivors

MD Anderson's Jim Allison named winner of 2015 Lasker-DeBakey Clinical Medical Research Award

Oxis Biotech executes worldwide license agreement to develop, commercialize novel cancer therapy

FDA grants Orphan Drug designation to Rigel's Fostamatinib for treatment of patients with ITP

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer